Highly potent HCV NS4B inhibitors with activity against multiple genotypes

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• Hepatitis C Virus (HCV) infection remains a significant global health concern.
• The NS4B protein is a crucial non-structural protein essential for HCV replication.
• Developing novel inhibitors targeting HCV NS4B is critical for effective antiviral therapies.

Purpose of the Study:

• To explore novel inhibitors of the HCV NS4B protein.
• To optimize compounds based on a 2-oxadiazoloquinoline scaffold for enhanced antiviral activity.
• To achieve broad-spectrum activity against various HCV genotypes.

Main Methods:

• Design and synthesis of novel 2-oxadiazoloquinoline derivatives.
• In vitro evaluation of antiviral activity against HCV NS4B.
• Structure-activity relationship (SAR) studies for optimization.

Main Results:

• Identification of a potent new series of HCV NS4B inhibitors.
• Demonstrated broad activity across multiple HCV genotypes.
• Inhibitor 1 exhibited nanomolar EC50 values across tested genotypes (e.g., 1a: 0.08 nM, 1b: 0.10 nM, 4a: 0.9 nM).

Conclusions:

• The 2-oxadiazoloquinoline scaffold is a promising basis for developing potent HCV NS4B inhibitors.
• Optimized compounds display broad genotype activity, suggesting potential for a pan-genotypic antiviral agent.
• Further development could lead to new therapeutic options for Hepatitis C treatment.